Study Title
ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Protocol ID
ANHL1931
Disease (Sub Disease)
Primary Mediastinal Large B-Cell Lymphoma
Diagnosis Stage
Newly Diagnosed
Location
NSW, QLD, VIC, WA
Sponsor
National Cancer Institute (NCI)
Collaborators
Children's Oncology Group
Links
Trial Status
Open
Sites
John Hunter Children's Hospital
The Children's Hospital at Westmead
Queensland Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
The Children's Hospital at Westmead
Queensland Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
2 Years and older
International registry ID's
NCT04759586
| Study Title | ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma |
|---|---|
| Protocol ID | ANHL1931 |
| Disease (Sub Disease) | Primary Mediastinal Large B-Cell Lymphoma |
| Diagnosis Stage | Newly Diagnosed |
| Location | NSW / QLD / VIC / WA |
| Sponsor | National Cancer Institute (NCI) |
| Collaborators | Children's Oncology Group |
| Links | https://clinicaltrials.gov/ct2/show/NCT04759586 |
| Trial Status | Open |
| Trial Open Date | 07/06/2021 |
| Sites | John Hunter Children's Hospital/ The Children's Hospital at Westmead/ Queensland Children's Hospital / Royal Children's Hospital / Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 2 Years and older |
| International registry ID's | NCT04759586 |